Literature DB >> 11790927

T wave alternans for ventricular arrhythmia risk stratification.

Ahmed F Osman1, Michael R Gold.   

Abstract

Identifying patients at high risk of sudden cardiac death is an important goal, given the magnitude of this problem. In this regard, T wave alternans (TWA) is a heart-rate-dependent measure of arrhythmia vulnerability. The predictive accuracy of this test is maximal at heart rates between 100 and 120 bpm, which are usually achieved with exercise or atrial pacing. TWA has been shown to predict inducibility of ventricular tachycardia with programmed stimulation and to predict spontaneous arrhythmic events. This test has been applied to diverse populations, including patients with coronary artery disease, nonischemic cardiomyopathy, congestive heart failure, and status post implantable defibrillators. Despite these encouraging results, the role of TWA to guide clinical therapy still must be better elucidated.

Entities:  

Mesh:

Year:  2002        PMID: 11790927     DOI: 10.1097/00001573-200201000-00001

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  3 in total

Review 1.  [Long QT syndrome and anaesthesia].

Authors:  S Rasche; T Koch; M Hübler
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

2.  Microvolt T-wave alternans as predictor of electrophysiological testing results in professional competitive athletes.

Authors:  Francesco Furlanello; Giorgio Galanti; Paolo Manetti; Andrea Capalbo; Nicola Pucci; Antonio Michelucci; Daniele Marangoni; Francesco Terrasi; Giacinto Pettinati; Riccardo Cappato
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-07       Impact factor: 1.468

3.  Association of Holter-based measures including T-wave alternans with risk of sudden cardiac death in the community-dwelling elderly: the Cardiovascular Health Study.

Authors:  Phyllis K Stein; Devang Sanghavi; Nona Sotoodehnia; David S Siscovick; John Gottdiener
Journal:  J Electrocardiol       Date:  2010-01-25       Impact factor: 1.438

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.